- Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
- Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
More ▼
Key statistics
On Friday, Cabaletta Bio Inc (CABA:NSQ) closed at 10.66, 11.97% above the 52 week low of 9.52 set on Jun 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.35 |
---|---|
High | 13.50 |
Low | 10.00 |
Bid | 10.45 |
Offer | 11.21 |
Previous close | 12.56 |
Average volume | 1.47m |
---|---|
Shares outstanding | 48.28m |
Free float | 45.05m |
P/E (TTM) | -- |
Market cap | 514.63m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼